Exploiting synthetic lethal interactions caused by specific mutations offers more promise, as in SMARCA4‐mutant cancers reliant on SMARCA2 or SMARCB1‐mutant tumors vulnerable to ncBAF‐targeting. This evidence concerns the gene SMARCA4 and cancer.